The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
Open accessAbstract
Aims: To evaluate apixaban single dose safety, tolerability, pharmacokinetics and pharmacodynamics and assess the effect of food on apixaban pharmacokinetics. Methods: A double‐blind, placebo‐controlled, single ascending‐dose, first‐in‐human study assessed apixaban safety, pharmacokinetics and pharmacodynamics in healthy subjects randomized to oral apixaban (n = 43; 0.5–2.5 mg as solution or 5–50 mg as tablets) or placebo (n = 14) under fasted conditions. An open label, randomized, two treatment crossover study investigated apixaban pharmacokinetics/pharmacodynamics in healthy subjects (n = 21) administered apixaban 10 mg in fasted and fed states. Both studies measured apixaban plasma concentration, international normalized ratio (INR), activated partial thromboplastin time (aPTT) and prothrombin time (PT) or a modified PT (mPT). Results: In the single ascending‐dose study increases in apixaban exposure appeared dose‐proportional. Median tmax occurred 1.5–3.3 h following oral administration. Mean terminal half‐life ranged between 3.6 and 6.8 h following administration of solution doses ≤2.5 mg and between 11.1 and 26.8 h for tablet doses ≥5 mg. Concentration‐related changes in pharmacodynamic assessments were observed. After a 50 mg dose, peak aPTT, INR and mPT increased by 1.2‐, 1.6‐ and 2.9‐fold, respectively, from baseline. In the food effect study: 90% confidence intervals of geometric mean ratios of apixaban Cmax and AUC in a fed vs. fasted state were within the predefined no effect (80–125%) range. Apixaban half‐life was approximately 11.5 h. The effect of apixaban on INR, PT and aPTT was comparable following fed and fasted administration. Conclusions: Single doses of apixaban were well tolerated with a predictable pharmacokinetic/pharmacodynamic profile and a half‐life of approximately 12 h. Apixaban can be administered with or without food.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Apixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483
Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M., & Palareti, G. (2008) · Chest · doi:10.1378/chest.08-0670 · Cited by 2,118
Lassen, M. R., Raskob, G. E., Gallus, A., Pineo, G., Chen, D., & Hornick, P. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62125-5 · Cited by 777
Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement
Lassen, M. R., Gallus, A., Raskob, G. E., Pineo, G., Chen, D., & Ramirez, L. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006885 · Cited by 775
Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans
Raghavan, N., Frost, C. E., Yu, Z., He, K., Zhang, H., Humphreys, W. G., Pinto, D., Chen, S., Bonacorsi, S., Wong, P. C., et al. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.023143 · Cited by 612
Self-citationEriksson, B. I., Quinlan, D. J., & Weitz, J. I. (2009) · Clinical Pharmacokinetics · doi:10.2165/0003088-200948010-00001 · Cited by 522
Fleisher, D., Li, C., Zhou, Y., Pao, L., & Karim, A. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936030-00004 · Cited by 506
Pinto, D. J. P., Orwat, M. J., Koch, S., Rossi, K. A., Alexander, R. S., Smallwood, A., Wong, P. C., Rendina, A. R., Luettgen, J. M., Knabb, R. M., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070245n · Cited by 402
Muscular exercise can cause highly pathological liver function tests in healthy men
Pettersson, J., Hindorf, U., Persson, P., Bengtsson, T., Malmqvist, U., Werkström, V., & Ekelund, M. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.03001.x · Cited by 357
Wang, Z., Frost, C., Shenker, A., & Barrett, Y. C. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-05-0328 · Cited by 356
Self-citationWONG, P. C., CRAIN, E. J., XIN, B., WEXLER, R. R., LAM, P. Y. S., PINTO, D. J., LUETTGEN, J. M., & KNABB, R. M. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.02939.x · Cited by 300
Stangier, J., Eriksson, B. I., Dahl, O. E., Ahnfelt, L., Nehmiz, G., Stähle, H., Rathgen, K., & Svärd, R. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005274550 · Cited by 296
Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays
HILLARP, A., BAGHAEI, F., FAGERBERG BLIXTER, I., GUSTAFSSON, K. M., STIGENDAL, L., STEN‐LINDER, M., STRANDBERG, K., & LINDAHL, T. L. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.04098.x · Cited by 288
Weitz, J. I., Hirsh, J., & Samama, M. M. (2008) · Chest · doi:10.1378/chest.08-0673 · Cited by 262
Kubitza, D., Becka, M., Zuehlsdorf, M., & Mueck, W. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006286904 · Cited by 254
BULLER, H., DEITCHMAN, D., PRINS, M., & SEGERS, A. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.03054.x · Cited by 252
Clinical Pharmacokinetics: Concepts and Applications
(1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-110-6-500_4 · Cited by 247
Sample size determination for bioequivalence assessment by means of confidence intervals.
Diletti, E., Hauschke, D., & Steinijans, V. W. (1991) · PubMed · Cited by 228
Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism
Eriksson, B. I., Quinlan, D. J., & Eikelboom, J. W. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-062209-095159 · Cited by 194
Beyond Hemoglobin A1c—Need for Additional Markers of Risk for Diabetic Microvascular Complications
Hirsch, I. B. (2010) · JAMA · doi:10.1001/jama.2010.785 · Cited by 184
Franco, V., Polanczyk, C. A., Clausell, N., & Rohde, L. E. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.12.036 · Cited by 161
Ufer, M. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-09-0659 · Cited by 129
Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro
Jiang, X., Crain, E. J., Luettgen, J. M., Schumacher, W., & Wong, P. C. (2009) · Thrombosis and Haemostasis · doi:10.1160/th08-07-0486 · Cited by 94
General Derivation of the Equation for Time to Reach a Certain Fraction of Steady State
Perrier, D. G., & Gibaldi, M. (1982) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600710432 · Cited by 72
Wong, P. C., Crain, E. J., WATSON, C. A., & XIN, B. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03503.x · Cited by 72
Interaction of Dietary Factors with Oral Anticoagulants
HARRIS, J. E. (1995) · Journal of the American Dietetic Association · doi:10.1016/s0002-8223(95)00158-1 · Cited by 58
Kurnik, D., Loebstein, R., Rabinovitz, H. R., et al. (2004) · Thrombosis and Haemostasis · doi:10.1160/th04-06-0346 · Cited by 58
Wong, P. C., WATSON, C. A., & Crain, E. J. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.03092.x · Cited by 47
Ieko, M., Tarumi, T., Takeda, M., Naito, S., Nakabayashi, T., & Koike, T. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7933.2004.00649.x · Cited by 40
A Novel Prothrombin Time Assay for Assessing the Anticoagulant Activity of Oral Factor Xa Inhibitors
Barrett, Y. C., Wang, Z., & Knabb, R. M. (2012) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029612441859 · Cited by 39
Self-citationWong, P. C., Crain, E. J., Watson, C. A., Wexler, R. R., Lam, P. Y. S., Quan, M. L. C., & Knabb, R. M. (2007) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-007-0017-9 · Cited by 34
Limitations of Traditional Anticoagulants
Hawkins, D. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.10.62s.36120 · Cited by 29
Groen, D. K., Harris, S., Colucci, S. V., & Apseloff, G. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010365548 · Cited by 1
Cited by
Narouze, S., Benzon, H. T., Provenzano, D. A., Buvanendran, A., De Andres, J., Deer, T. R., Rauck, R., & Huntoon, M. A. (2015) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000223 · Cited by 362
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review
Byon, W., Garonzik, S., Boyd, R. A., & Frost, C. E. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00775-z · Cited by 348
Self-citationFrost, C., Nepal, S., Wang, J., Schuster, A., Byon, W., Boyd, R. A., Yu, Z., Shenker, A., Barrett, Y. C., Mosqueda‐Garcia, R., et al. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12106 · Cited by 286
Self-citationWang, X., Tirucherai, G., Marbury, T. C., Wang, J., Chang, M., Zhang, D., Song, Y., Pursley, J., Boyd, R. A., & Frost, C. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.628 · Cited by 286
Self-citationUpreti, V. V., Wang, J., Barrett, Y. C., Byon, W., Boyd, R. A., Pursley, J., LaCreta, F. P., & Frost, C. E. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12114 · Cited by 269
Self-citation
Metadata
- Authors
- Frost, C., Wang, J., Nepal, S., Schuster, A., Barrett, Y. C., Mosqueda‐Garcia, R., Reeves, R. A., & LaCreta, F.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2013-01-10
- Volume
- 75
- Issue
- 2
- Pages
- 476-487
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W1507763452
- Cited by
- 370
- References
- 34
- FWCI
- 24.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.